Abstract
The efficacy of Sandostatin® (octreotide) was evaluated in a group of patients with treatment-resistant aggressive malignancies manifested by rapidly enlarging metastases and associated endocrine syndromes. The malignancies included carcinoid and pancreatic endocrine tumors of the gastroenteropancreatic (GEP) system, as well as hormone-sensitive tumors (breast cancer) and neuroendocrine tumors of non-GEP origin (medullary carcinoma of thyroid and small cell lung cancer). The latter group was specifically included to permit evaluation of the effects of Sandostatin on both gastrointestinal and endocrine physiology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ghirlanda G, Uccioli L, Perri F, Altomonte L, Bertoli A, Manna R, Fruti L, Greco AV: Epidermal growth factor, somatostatin, and psoriasis. Lancet 1983: 1; 65
Lamberts SWJ, Uitterlinden P, Verschoor L, Krijin J, Dungen V, Del Pozo E: Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 1985: 313; 1576–1580
Reubi JC: A somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth. Acta Endocrinol 1985: 109; 108–114
Schally AV, Comaru-Schally AM, Redding TW: Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med 1984: 1975; 259–281
Setyone-Han B, Henkelman MS, Foekens JA, Klign JGM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987: 47; 1556–1570
WHO handbook for reporting results of cancer treatment. Publication No. 48. World Health Organization, Geneva, Switzerland, 1979
Wood SM, Kraenzlin ME, Adrian TE, Bloom SR: Treatments of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue; symptomatic and peptide responses. Gut 1985: 26; 438–444
Zeggori M, Susini C, Viguerie W, Esteve JP, Vaysse W, Ribet A: Tumor promoter inhibition of cellular binding of somatostatin. BBRC 1985: 128; 850–857
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Verlag, Berlin Heidelberg
About this paper
Cite this paper
Sagman, U., Fine, S. (1989). Sandostatin® in the Treatment of Advanced Malignancies. In: O’Dorisio, T.M. (eds) Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61328-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-61328-9_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64794-9
Online ISBN: 978-3-642-61328-9
eBook Packages: Springer Book Archive